Table 3. Adalimumab effectiveness at week 12 in all patients and in patients with a history of anterior uveitis (observed values).
| All patients (n = 1250) | History of AU* (n = 274) | Recent history of AU† (n = 106) | Symptomatic AU at baseline (n = 28) | Chronic AU‡ (n = 43) | |
| ASAS40, % | 53.7 | 54.5 | 55.1 | 56.0 | 52.4 |
| BASDAI 50, % | 57.2 | 60.7 | 61.8 | 66.7 | 59.5 |
| ASAS partial remission, % | 27.7 | 32.5 | 32.7 | 40.0 | 33.3 |
| CRP, mg/dl, mean (SD) | 0.8 (1.4) | 1.0 (1.8) | 1.2 (2.2) | 1.6 (2.6) | 0.9 (0.9) |
| CRP absolute change, mean (SD) | −1.4 (2.5) | −1.9 (3.3) | −2.3 (4.5) | −3.8 (5.5) | −2.6 (3.2) |
*History of AU, history of at least one AU flare anytime. †Recent history of AU, history of at least one AU flare in the past year. ‡Chronic uveitis refers to persistent AU flares of at least 3-month duration and with relapse within less than 3 months according to the Standardization of Uveitis Nomenclature Working Group.6
ASAS, Assessments in Spondyloarthritis International Society criteria for response, partial remission (value of <2 on a 0–10-point scale in each of the four ASAS20 domains); AU, anterior uveitis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CRP, C-reactive protein.